Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

被引:20
作者
Reza Taherkhani [1 ]
Fatemeh Farshadpour [1 ]
机构
[1] the Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences
关键词
Hepatitis C virus; Epidemiology; Elimination; Injecting drug user; revention; Vaccine; Diagnosis; Treatment;
D O I
暂无
中图分类号
R512.63 [];
学科分类号
100401 ;
摘要
Today, with the introduction of interferon-free direct-acting antivirals and outstanding progresses in the prevention, diagnosis and treatment of hepatitis C virus(HCV) infection, the elimination of HCV infection seems more achievable. A further challenge is continued transmission of HCV infection in high-risk population specially injecting drug users(IDUs) as the major reservoir of HCV infection. Considering the fact that most of these infections remain undiagnosed, unidentified HCVinfected IDUs are potential sources for the rapid spread of HCV in the community. The continuous increase in the number of IDUs along with the rising prevalence of HCV infection among young IDUs is harbinger of a forthcoming public health dilemma, presenting a serious challenge to control transmission of HCV infection. Even the changes in HCV genotype distribution attributed to injecting drug use confirm this issue. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients through risk-based screening to mitigate the risk of HCV transmission in the IDUs community and, consequently, in the society. Meanwhile, raising general awareness of HCV infection, diagnosis and treatment through public education should be the core activity of any harm reduction intervention, as the root cause of failure in control of HCV infection has been lack of awareness among young drug takers. In addition, effective prevention, comprehensive screening programs with a specific focus on high-risk population, accessibility to the new anti-HCV treatment regimens and public education should be considered as the top priorities of any health policy decision to eliminate HCV infection.
引用
收藏
页码:1239 / 1252
页数:14
相关论文
共 48 条
[11]  
An overview on hepatitis C virus genotypes and its control[J] . Faisal Nouroz,Sidra Shaheen,Ghulam Mujtaba,Shumaila Noreen.Egyptian Journal of Medical Human Genetics . 2015 (4)
[12]  
Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs[J] . Jason Grebely,Philip Bruggmann,Carla Treloar,Jude Byrne,Tim Rhodes,Gregory J. Dore.International Journal of Drug Policy . 2015 (10)
[13]   Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment [J].
Adkison, Kimberly K. ;
Gan, Jianjun ;
Elko-Simms, Lucinda ;
Gardner, Stephen ;
Dumont, Etienne ;
Jones, Lori S. ;
Saunders, Joanne ;
Marbury, Thomas ;
Smith, William ;
Berg, Jolene ;
Galloway, Christopher ;
Stump, Patrick J. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09) :1042-1050
[14]   Global Distribution and Prevalence of Hepatitis C Virus Genotypes [J].
Messina, Jane P. ;
Humphreys, Isla ;
Flaxman, Abraham ;
Brown, Anthony ;
Cooke, Graham S. ;
Pybus, Oliver G. ;
Barnes, Eleanor .
HEPATOLOGY, 2015, 61 (01) :77-87
[15]  
A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing[J] . Thomas F. Baumert,Catherine Fauvelle,Diana Y. Chen,Georg M. Lauer.Journal of Hepatology . 2014 (1)
[16]  
Global epidemiology and genotype distribution of the hepatitis C virus infection[J] . Erin Gower,Chris Estes,Sarah Blach,Kathryn Razavi-Shearer,Homie Razavi.Journal of Hepatology . 2014 (1)
[17]  
Seronegative occult hepatitis C virus infection: Clinical implications[J] . Vicente Carre?o.Journal of Clinical Virology . 2014
[18]  
All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐na?ve patients with genotype 1 HCV infection[J] . David L. Wyles,Maribel Rodriguez‐Torres,Eric Lawitz,Mitchell L. Shiffman,Stanislas Pol,Robert W. Herring,Benedetta Massetto,Bittoo Kanwar,James D. Trenkle,Phil S. Pang,Yanni Zhu,Hongmei Mo,Diana M. Brainard,G. Mani Subramanian,John G. McHutchison,Fran?ois Habersetzer,Mark S. Sulkowski.Hepatology . 2014 (1)
[19]  
Why is it so difficult to develop a hepatitis C virus preventive vaccine?[J] . C. Zingaretti,R. De Francesco,S. Abrignani.Clin Microbiol Infect . 2014
[20]  
Is dental extraction a risk factor for contracting HCVinfection:Abs,RNA and genotype detection .2 Al-Kubaisy W,Al-Naggar RA,Ibrahim NSN,Bobryshev YV,AlKubaisy MW. Oral Biol Dentist . 2014